In these models, the use of TG2 inhibitors have helped to confirm and to better define the role of TG2 in CD pathogenesis and have opened the way to experimentation with some drugs in preclinical and clinical trials with encouraging results. The gene discussed is TGM2; the disease is Cowden disease.